Cargando…

Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry

OBJECTIVE: Randomized controlled trials (RCTs) in biologic-naïve rheumatoid arthritis (RA) patients with high disease activity and inadequate response/intolerance to methotrexate have shown interleukin-6 (IL-6) receptor inhibitors (IL-6Ri) to be superior to tumor necrosis factor inhibitors (TNFi) as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sebba, Anthony, Bingham, Clifton O., Bykerk, Vivian P., Fiore, Stefano, Ford, Kerri, Janak, Jud C., Pappas, Dimitrios A., Blachley, Taylor, Dave, Swapna S., Kremer, Joel M., Yu, Miao, Choy, Ernest
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345054/ https://www.ncbi.nlm.nih.gov/pubmed/37060528 http://dx.doi.org/10.1007/s10067-023-06588-7

Ejemplares similares

The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry
por: Padula, Anthony S., et al.
Publicado: (2022)

Characteristics of Patients with Crohn’s Disease With or Without Perianal Fistulae in the CorEvitas Inflammatory Bowel Disease Registry
por: Fan, Yanni, et al.
Publicado: (2022)

Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2023)

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2022)

Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen‐B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry
por: Walsh, Jessica A., et al.
Publicado: (2021)

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry
por: Yu, Chen, et al.
Publicado: (2022)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry
por: McLean, Robert R., et al.
Publicado: (2023)

Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas’ Inflammatory Bowel Disease Registry
por: Cross, Raymond K, et al.
Publicado: (2022)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry
por: McLean, Robert R., et al.
Publicado: (2023)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study
por: Dua, Anisha B., et al.
Publicado: (2023)

Santa Evita /
por: Martínez, Tomás Eloy
Publicado: (1995)

Evita : imagenes de una pasion
Publicado: (1997)

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis
por: Cappelli, Laura C, et al.
Publicado: (2022)

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab
por: Choy, Ernest, et al.
Publicado: (2022)

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
por: Jones, G, et al.
Publicado: (2010)

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
por: Pappas, Dimitrios A, et al.
Publicado: (2021)

Beyond Methotrexate and Biologics in RA – Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium
por: Chatzidionysiou, Katerina
Publicado: (2020)

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set
por: Bykerk, Vivian P, et al.
Publicado: (2016)

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2021)

Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry
por: Manders, Sofie H M, et al.
Publicado: (2015)

EVITA: a tool for the early EValuation of pharmaceutical Innovations with regard to Therapeutic Advantage
por: Püntmann, Isabel, et al.
Publicado: (2010)

Identification and mechanistic analysis of an inhibitor of the CorC Mg(2+) transporter
por: Huang, Yichen, et al.
Publicado: (2021)

Hydroxychloroquine and the risk of respiratory infections among RA patients
por: Kremer, Joel M, et al.
Publicado: (2020)

Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?
por: Kwok, Seung-Ki
Publicado: (2014)

Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score
por: Gaiser, Maria R., et al.
Publicado: (2019)

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
por: O’Mahony, Alison, et al.
Publicado: (2018)

Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice
por: Pappas, Dimitrios A., et al.
Publicado: (2019)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Left ventricular pseudoaneurysm after ascending, arch and descending aortic replacement with Evita Open Plus® prosthesis
por: Echevarría, JR, et al.
Publicado: (2013)

Effects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial
por: Zittermann, Armin, et al.
Publicado: (2018)

The EVITA framework for evidence-based mental health policy agenda setting in low- and middle-income countries
por: Votruba, Nicole, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l5l9pbhoesdbho2vb5muq588gn